PositiveID (PSID) Awarded U.S. Patent No. 8,133,451 for First-of-Its-Kind Detection System for Molecular Biological Diagnostics
3/20/2012 9:39:23 AM
DELRAY BEACH, Fla., March 20, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense industry, announced today that it was awarded U.S. Patent No. 8,133,451 for its Dragonfly™ Rapid MDx Cartridge-based diagnostic system, which provides the ability to deliver molecular diagnostic results from a sample in less than 30 minutes. Dragonfly enables accurate diagnostics leading to the potential treatment scenarios at the point of care that are not possible with existing systems.